EU approval for Tecentriq combo
The approval of the monoclonal antibody was based on results from the Phase III IMpassion130 study.
Read More
Tag: Abraxane
Priority review for Roche’s Tecentriq/Abraxane combo
US regulators are undertaking a priority review of Roche’s Tecentriq in combination with Abraxane for the treatment of triple-negative breast cancer.
Read More
Pancreatic cancer patients in England get CDF access to Abraxane
Patients with pancreatic cancer living in England can from today potentially get access to a new treatment option after funding for Celgene’s Abraxane was approved for NHS use.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
